VIEMED HEALTHCARE, INC.
Business
Viemed Healthcare is a provider of home medical equipment and post-acute healthcare services in the United States, focused on respiratory, chronic care, and women's health. The company offers respiratory disease management, neuromuscular care, sleep apnea treatment, oxygen therapy, supply fulfillment, women's health products, and healthcare staffing services, primarily through home-based clinical delivery by licensed respiratory therapists. Viemed operates across all 50 U.S. states and serves patients through Medicare, Medicaid, and commercial insurance reimbursement, with respiratory device rentals and related clinical services representing its largest revenue stream.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 270 | 224 | 183 | 139 | 117 | |
| Cost of revenue | 115 | 91 | 70 | 54 | 44 | |
| Gross profit | 155 | 133 | 113 | 85 | 73 | |
| Selling, general and administrative | 121 | 106 | 88 | 68 | 55 | |
| Research and development | 3 | 3 | 3 | 3 | 2 | |
| Stock-based compensation | 9 | 6 | 6 | 5 | 5 | |
| Depreciation and amortization | 1 | 1 | 1 | 1 | — | |
| Loss (gain) on disposal of property and equipment | −2 | −2 | 645,000 | 346,000 | 448,000 | |
| Other expense (income), net | −252,000 | 173,000 | −98,000 | −989,000 | −2 | |
| Income from operations | 23 | 18 | 14 | 8 | 12 | |
| Income (loss) from investments | 0 | −954,000 | 485,000 | 935,000 | 1 | |
| Interest expense, net | −1 | −776,000 | −424,000 | −197,000 | −318,000 | |
| Net income before taxes | 22 | 16 | 14 | 9 | 13 | |
| Provision for income taxes | 6 | 5 | 4 | 3 | 3 | |
| Net income | 15 | 11 | 10 | 6 | — | |
| Net income attributable to noncontrolling interest | 442,000 | 144,000 | 0 | 0 | — | |
| Net income attributable to Viemed Healthcare, Inc. | 15 | 11 | 10 | 6 | 9 | |
| Basic (in USD per share) | 0.38 | 0.29 | 0.27 | 0.16 | 0.23 | |
| Diluted (in USD per share) | 0.37 | 0.28 | 0.25 | 0.16 | 0.22 | |
| Basic (in shares) | 39 | 39 | 38 | 39 | 39 | |
| Diluted (in shares) | 41 | 41 | 40 | 40 | 41 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 14 | 18 | 13 | 17 | 28 | |
| Accounts receivable, net | 26 | 25 | 18 | 15 | 13 | |
| Inventory | 5 | 4 | 5 | 4 | 2 | |
| Income tax receivable | 227,000 | 0 | 0 | 26,000 | 2 | |
| Prepaid expenses and other assets | 4 | 6 | 2 | 4 | 2 | |
| Total current assets | 48 | 53 | 38 | 40 | 47 | |
| Property and equipment, net | 79 | 76 | 74 | 68 | — | |
| Finance lease right-of-use assets | 0 | 50,000 | 401,000 | 0 | — | |
| Operating lease right-of-use assets | 4 | 3 | 3 | 694,000 | — | |
| Equity investments | 3 | 3 | 2 | — | — | |
| Deferred tax asset | 5 | 8 | 5 | 3 | 5 | |
| Identifiable intangibles, net | 1 | 848,000 | 567,000 | 0 | — | |
| Goodwill | 59 | 33 | 30 | 0 | — | |
| Total long-term assets | 151 | 124 | 117 | 77 | 71 | |
| TOTAL ASSETS | 199 | 177 | 155 | 117 | 118 | |
| Trade payables | 7 | 5 | 4 | 3 | 3 | |
| Deferred revenue | 8 | 7 | 6 | 5 | 4 | |
| Income taxes payable | 0 | 4 | 2 | 0 | 0 | |
| Accrued liabilities | 24 | 20 | 18 | 11 | 9 | |
| Finance lease liabilities, current portion | 0 | 50,000 | 256,000 | 0 | — | |
| Operating lease liabilities, current portion | 1 | 811,000 | 678,000 | 495,000 | — | |
| Current portion of long-term debt | 1 | 409,000 | 1 | 0 | 1 | |
| Total current liabilities | 41 | 37 | 32 | 19 | 18 | |
| Accrued liabilities | 922,000 | 846,000 | 558,000 | 889,000 | 757,000 | |
| Operating lease liabilities, less current portion | 2 | 2 | 2 | 199,000 | — | |
| Long-term debt | 11 | 4 | 6 | 0 | 4 | |
| Total long-term liabilities | 15 | 6 | 9 | 1 | 5 | |
| TOTAL LIABILITIES | 56 | 44 | 41 | 20 | 23 | |
| Commitments and Contingencies | 0 | 0 | 0 | 0 | 0 | |
| Common stock - No par value: unlimited authorized; 38,019,082 and 39,132,897 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 17 | 23 | 19 | 15 | 14 | |
| Additional paid-in capital | 22 | 18 | 16 | 12 | 8 | |
| Retained earnings | 103 | 90 | 79 | 70 | 73 | |
| TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | 142 | 131 | 114 | 97 | 95 | |
| Noncontrolling interest in subsidiary | 2 | 2 | 0 | — | — | |
| TOTAL SHAREHOLDERS' EQUITY | 144 | 133 | 114 | 97 | 95 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 199 | 177 | 155 | 117 | 118 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 29 | 25 | 22 | 16 | — | |
| Stock-based compensation expense | 9 | 6 | 6 | 5 | 5 | |
| Distributions of earnings received from equity method investments | 0 | 147,000 | 980,000 | 1 | 416,000 | |
| Income from equity method investments | 0 | −261,000 | −485,000 | −935,000 | −1 | |
| Loss (income) from debt investment | 0 | 1 | −219,000 | 0 | — | |
| Amortization of deferred financing costs | 228,000 | 187,000 | 0 | 0 | — | |
| Deferred income tax expense (benefit) | 3 | −4 | −1 | 2 | 4 | |
| Accounts receivable, net | 1 | −6 | −1 | −3 | −7 | |
| Inventory | 59,000 | 574,000 | −472,000 | 301,000 | −212,000 | |
| Prepaid expenses and other assets | −503,000 | 544,000 | 2 | −3 | −226,000 | |
| Trade payables | 479,000 | 359,000 | −859,000 | −318,000 | 133,000 | |
| Deferred revenue | 359,000 | 364,000 | 851,000 | 871,000 | 344,000 | |
| Accrued liabilities | 255,000 | 3 | 5 | 3 | −4 | |
| Income tax payable/receivable | −4 | 2 | 2 | 2 | −2 | |
| Net cash provided by operating activities | 52 | 39 | 45 | 28 | 22 | |
| Purchase of property and equipment | −40 | −38 | −26 | −23 | −20 | |
| Investment in equity investments | 0 | −1 | −20,000 | −141,000 | −599,000 | |
| Cash paid for acquisitions, net of cash acquired | −26 | −3 | −29 | 0 | — | |
| Proceeds from sale of debt security | 0 | 750,000 | 0 | 0 | — | |
| Proceeds from sale of property and equipment | 16 | 10 | 3 | 1 | 596,000 | |
| Net cash used in investing activities | −50 | −31 | −52 | −24 | −20 | |
| Proceeds from exercise of options | 1 | 1 | 1 | 283,000 | 112,000 | |
| Proceeds from term notes | 9 | 0 | 5 | 0 | — | |
| Principal payments on term notes | −730,000 | −1 | −4 | −6 | −152,000 | |
| Proceeds from revolving credit facilities | 13 | 3 | 8 | 0 | — | |
| Principal payments on revolving credit facilities | −13 | −5 | −7 | 0 | — | |
| Payments for debt issuance costs | −115,000 | −192,000 | 0 | 0 | — | |
| Shares redeemed to pay income tax | −2 | −1 | −594,000 | −143,000 | −1 | |
| Shares repurchased under the share repurchase program | −13 | 0 | 0 | −10 | 0 | |
| Repayments of finance lease liabilities | −50,000 | −338,000 | −157,000 | 42,000 | — | |
| Distributions to non-controlling interest | −374,000 | −36,000 | 0 | 0 | — | |
| Net cash provided by (used in) financing activities | −6 | −4 | 3 | −15 | −5 | |
| Net increase (decrease) in cash and cash equivalents | −4 | 5 | −4 | −11 | −3 | |
| Cash paid during the period for interest | 874,000 | 950,000 | 851,000 | 231,000 | 351,000 | |
| Cash paid during the period for income taxes, net of refunds | 7 | 7 | 4 | −846,000 | 2 | |
| Non-cash change in debt from the reclassification of debt issuance costs | 0 | 0 | −594,000 | 0 | — | |
| Net non-cash changes to operating lease | 0 | 0 | −41,000 | 530,000 | — | |
| Equipment and other fixed asset purchases payable at end of period | 3 | 2 | 1 | 739,000 | — | |
| Equipment sales receivable at end of period | 0 | 3 | 0 | 0 | — | |
| Non-cash consideration received for sale of debt security | 0 | 125,000 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is VIEMED HEALTHCARE, INC.'s CIK number?
VIEMED HEALTHCARE, INC.'s SEC CIK number is 0001729149 (1729149). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find VIEMED HEALTHCARE, INC.'s SEC filings?
All of VIEMED HEALTHCARE, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did VIEMED HEALTHCARE, INC. last report earnings?
VIEMED HEALTHCARE, INC. (VMD) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001729149-26-000028). This is VIEMED HEALTHCARE, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is VIEMED HEALTHCARE, INC.'s most recent earnings 8-K?
VIEMED HEALTHCARE, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001729149-26-000028. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View VIEMED HEALTHCARE, INC.'s latest earnings 8-K →
Look up any company's CIK number →